Drug recall
Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial…
FDA recall event 90959 · Class III · Genentech Inc
Key facts
| Event ID | 90959 |
|---|---|
| Recall numbers | D-0025-2023 |
| Recalling firm | Genentech Inc |
| Product type | Drugs |
| Products | Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo… |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm Initiated |
| Reason for recall | Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning. |
| Initiation date | Oct 18, 2022 |
| Report date | Nov 9, 2022 |
| Termination date | Apr 17, 2024 |
| City | South San Francisco |
| State | CA |
| Country | United States |
| FEI number | 2917293 |
At a glance
- 1–9 Products in this recall
- 10–99 FDA inspections of this firm (FEI)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug and product recalls
FDA enforcement reports list recalls of drugs, biologics, foods and other FDA-regulated products, classified by the potential health hazard.
Source: U.S. Food and Drug Administration (FDA), Enforcement Reports · Source date: